Related Experiment Videos
Cisplatin as a radiosensitizer in clinical practice: a pilot study
1Department of Oncology, North Tai Ping Road Hospital Cancer Center, Beijing, China.
Tumori
|February 28, 1991
Summary
This study shows that combining cisplatin chemotherapy with radiotherapy effectively treats inoperable cancers, achieving high response rates and improved survival, particularly for complete responders.
Area of Science:
- Oncology
- Medical Oncology
- Radiotherapy
Background:
- Inoperable cancers present significant treatment challenges.
- Combination therapies are explored to improve patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and toxicity of combined cisplatin and radiotherapy in patients with inoperable cancers.
- To assess treatment response and survival rates.
Main Methods:
- Fifty-four patients received weekly cisplatin (40 mg/week, total 160-320 mg) concurrently with radiotherapy (50-70 Gy).
- Cisplatin blood concentrations were measured.
- Response was assessed by complete response (CR) and partial response (PR).
Main Results:
- An overall response rate of 89% was observed (56% CR, 33% PR).
- One-year survival for CR patients was 88%, compared to 33% for PR patients.
- Moderate toxicity, including emesis and myelosuppression (11% Grade III), was noted.
Conclusions:
- Combined cisplatin and radiotherapy demonstrates high efficacy in treating inoperable cancers.
- Complete response is associated with significantly better survival outcomes.
- Further controlled studies are recommended to confirm these findings.